Deane Retirement Strategies Inc. Purchases Shares of 31,245 Zoetis Inc. $ZTS

Key Points

• Deane Retirement Strategies acquired 31,245 Zoetis shares worth approximately $2.25 million, while institutional investors collectively own 92.8% of the company.
• Zoetis beat quarterly EPS expectations with adjusted earnings of $1.87 per share, but revenue of $2.47 billion fell short of forecasts amid weaker veterinary traffic and competitive pressure.
• The company cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 and revenue of $9.1–$9.3 billion. Shares opened at $72.53, near their 52-week low, while analysts held an average “Hold” rating with a $115.50 price target.

Deane Retirement Strategies Inc. acquired a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 31,245 shares of the company's stock, valued at approximately $2,247,000.

Other hedge funds have also made changes to their positions in the company. Everhart Financial Group Inc. acquired a new stake in shares of Zoetis during the 2nd quarter worth about $202,000. Chemistry Wealth Management LLC raised its stake in Zoetis by 504.4% during the 2nd quarter. Chemistry Wealth Management LLC now owns 19,696 shares of the company's stock worth $1,415,000 after acquiring an additional 16,437 shares in the last quarter. Seilern Investment Management Ltd lifted its position in Zoetis by 44.3% in the second quarter. Seilern Investment Management Ltd now owns 460,006 shares of the company's stock valued at $33,056,000 after acquiring an additional 141,233 shares during the last quarter. Rockland Trust Co. boosted its stake in Zoetis by 27.2% in the second quarter. Rockland Trust Co. now owns 203,771 shares of the company's stock valued at $14,643,000 after acquiring an additional 43,616 shares in the last quarter. Finally, Trust Point Inc. boosted its stake in Zoetis by 9.2% in the second quarter. Trust Point Inc. now owns 4,912 shares of the company's stock valued at $353,000 after acquiring an additional 412 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Morgan Stanley set a $85.00 target price on Zoetis in a report on Friday. Citigroup reduced their price objective on Zoetis from $145.00 to $112.00 and set a "buy" rating for the company in a research note on Monday, May 18th. JPMorgan Chase & Co. decreased their price objective on Zoetis from $130.00 to $115.00 and set an "overweight" rating for the company in a report on Friday. Wall Street Zen lowered shares of Zoetis from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. Finally, HSBC reduced their price target on shares of Zoetis from $140.00 to $95.00 and set a "buy" rating for the company in a research report on Monday, July 6th. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Zoetis presently has an average rating of "Hold" and an average price target of $115.50.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $72.53 on Monday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company has a market cap of $30.41 billion, a P/E ratio of 11.95, a PEG ratio of 1.21 and a beta of 0.73. Zoetis Inc. has a 52 week low of $71.47 and a 52 week high of $160.48. The company has a 50-day moving average price of $76.66 and a 200 day moving average price of $100.58.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analysts' expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm's quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts predict that Zoetis Inc. will post 6.43 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis's dividend payout ratio is presently 34.93%.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Frank A. Damelio bought 6,650 shares of the firm's stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.22% of the company's stock.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source